Novo Nordisk to acquire Inversago Pharma for up to $1.08 Billion, expanding obesity drug portfolio
The Danish pharmaceutical company Novo Nordisk is set to acquire Inversago Pharma, a privately held obesity drug manufacturer, for a potential sum of $1.08 billion.